leadf
logo-loader
viewOpen Orphan PLC

Venn Life Sciences boss hopes to secure more million euro contracts

Tony Richardson, chief executive of Venn Life Sciences (LON:VENN), says the clinical research organisation’s key objective is to pitch for bigger pieces of business resulting in significant multi-million euro contracts.

Richardson’s prediction follows the announcement of a €1mln contract from a French biotech.  Venn has worked with the unnamed client on a previous clinical trial and Richardson says more large repeat contracts make the delivery of future growth ‘a little easier.’

Quick facts: Open Orphan PLC

Price: 28.75 GBX

AIM:ORPH
Market: AIM
Market Cap: £192.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan first half: 'period of integration, restructuring and setting...

Proactive Analyst Emma Ulker talks through how Open Orphan (LON:ORPH) performed in the first half of the year.  In the six-month period to June 2020, the company focused on integration and restructuring following its acquisition of lab services and challenge studies specialist hVIVO in...

on 30/9/20

2 min read